Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

See all formats and pricing
More options …
Volume 50, Issue 11


γ′ Fibrinogen as a novel marker of thrombotic disease

David H. Farrell
  • Corresponding author
  • Department of Medicine, Division of Cardiovascular Medicine, Oregon Health and Science University, Portland, OR, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2012-03-16 | DOI: https://doi.org/10.1515/cclm-2012-0005


γ′ Fibrinogen is an isoform of fibrinogen that normally constitutes about 7% of total plasma fibrinogen, and arises from an alternative processing event in the γ chain mRNA. γ′ Fibrinogen is a newly-emerging cardiovascular disease (CVD) risk factor that appears to have an independent association with CVD from that of total fibrinogen, which is itself a well-established CVD risk factor. γ′ Fibrinogen shows a significant association with coronary artery disease and myocardial infarction in at least four case-control studies, including the Stockholm Coronary Artery Risk Factor study and the Framingham Heart Study. γ′ Fibrinogen is also significantly associated with stroke, as shown in the Erasmus Stroke Study and others. The role of genetic polymorphisms in the association between γ′ fibrinogen and CVD is under active investigation. γ′ Fibrinogen increases during inflammation, and is differentially regulated from total fibrinogen under pathologic conditions, as demonstrated in the Periodontitis and Vascular Events study. The association between γ′ fibrinogen and venous thromboembolism remains unclear, however, with some studies showing an inverse association with γ′ fibrinogen levels and other studies showing the opposite.

Keywords: cardiovascular disease; γ′ fibrinogen; inflammation; risk marker; thromboembolism; thrombosis

About the article

David H. Farrell

David H. Farrell, PhD, is a Professor of Medicine in the Division of Cardiovascular Medicine at the Oregon Health and Science University, and has appointments in the Department of Molecular and Medical Genetics and the Department of Physiology and Pharmacology. He is also Founder and Chief Scientific Officer of Gamma Therapeutics, Inc., an Oregon-based early stage biotechnology venture developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry. Prof. Farrell is currently Co-Chair of the Thrombosis 2 Committee of the American Heart Association and on the Editorial Board of the open access journal Thrombosis. His primary research interests are in the biochemistry, genetics, regulation, and epidemiology of the blood clotting factor fibrinogen.

Corresponding author: David H. Farrell, PhD, Division of Cardiovascular Medicine, Department of Medicine, School of Medicine, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA Phone: +1 503 494 8602, Fax: +1 503 222 2306

Received: 2012-01-05

Accepted: 2012-02-16

Published Online: 2012-03-16

Published in Print: 2012-11-01

Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 50, Issue 11, Pages 1903–1909, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2012-0005.

Export Citation

©2012 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Xianming Fei, Huan Wang, Lei Jiang, Tongwei Zhao, Maoliang Cheng, and Wufeng Yuan
Technology in Cancer Research & Treatment, 2017, Page 153303461771415
Etheresia Pretorius, Sthembile Mbotwe, Janette Bester, Christopher J. Robinson, and Douglas B. Kell
Journal of The Royal Society Interface, 2016, Volume 13, Number 122, Page 20160539
Duke Appiah, Susan R. Heckbert, Mary Cushman, Bruce M. Psaty, and Aaron R. Folsom
Thrombosis Research, 2016, Volume 143, Page 50
Aaron R. Folsom, Weihong Tang, Kristen M. George, Susan R. Heckbert, Richard F. MacLehose, Mary Cushman, and James S. Pankow
Thrombosis Research, 2016, Volume 139, Page 44
Ravi Kant Upadhyay
Journal of Lipids, 2015, Volume 2015, Page 1
Chantelle M. Rein-Smith, Nathan W. Anderson, and David H. Farrell
Thrombosis Research, 2013, Volume 131, Number 1, Page 89
Inmaculada Jorge, Elena Burillo, Raquel Mesa, Lucía Baila-Rueda, Margoth Moreno, Marco Trevisan-Herraz, Juan Carlos Silla-Castro, Emilio Camafeita, Mariano Ortega-Muñoz, Elena Bonzon-Kulichenko, Isabel Calvo, Ana Cenarro, Fernando Civeira, and Jesús Vázquez
Journal of Proteomics, 2014, Volume 106, Page 61
Donya Mohebali, David Kaplan, McKenzie Carlisle, Mark A. Supiano, and Matthew T. Rondina
Journal of the American Geriatrics Society, 2014, Volume 62, Number 3, Page 529
N. J. Menzies-Gow, H. Wray, S. R. Bailey, P. A. Harris, and J. Elliott
Equine Veterinary Journal, 2014, Volume 46, Number 3, Page 317

Comments (0)

Please log in or register to comment.
Log in